Severe type 2 asthma: a touchEXPERT OPINIONS

Introduction

Watch leading experts discuss how to identify, assess and manage patients with severe type 2 asthma and consider the optimal use of biologic therapies to improve patient outcomes

This activity is intended for asthma specialists, respiratory care nurses, primary care physicians and other health care professionals involved in the treatment of patients with severe asthma.

Learning Objectives

After watching this touchEXPERT OPINIONS, you should be able to:

Identify patients with severe type 2 asthma promptly, including those with co-morbidities
Describe the inflammatory pathways that drive type 2 asthma and are targeted by biologic therapies
Summarize the data supporting the use of biologics in patients with type 2 severe asthma, including those with co-morbidities

About PROF. SANTIAGO QUIRCE

Santiago Quirce has been Head of the Department of Allergy at University Hospital La Paz, Madrid, Spain since 2007. He graduated in Medicine from the University of Santander, Spain, in 1983, and he obtained his PhD at the University of Cantabria in 1991. After completing specialty training in Allergology at Ramón y Cajal Hospital in Madrid, he spent one year as Research Fellow at Vancouver General Hospital, Respiratory Division, University of British Columbia (Canada). Then he joined Fundación Jiménez Díaz at Madrid, where he spent 9 years as a consultant allergist and clinical researcher.

Prof. Quirce has a broad research interest including asthma, rhinitis, and occupational allergy.

Prof. Quirce has edited and authored numerous publications and peer-reviewed papers, including 10 books. He has been a board member of the Asthma Committee of the World Allergy Organization (WAO), chair of the of the Asthma Committee of the Spanish Society of Allergy and Clinical Immunology (SEAIC) and chair of the Interest Group on Occupational Allergy of the European Academy of Allergy and Clinical Immunology (EAACI).

Disclosures: Consultant to ALK, AstraZeneca, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Teva, and has received lecture fees from AstraZeneca, Chiesi, GlaxoSmithKline, Leti, Mundipharma, Sanofi and Novartis.

touchCONGRESS Expert Interviews:
Advanced Breast Cancer

Touch Respiratory

touchEXPERT OPINIONS

Severe type 2 asthma: Using biologics to move beyond symptom reduction

Introduction

Learning Objectives

Please feed back on these touchEXPERT OPINIONS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Interviews: Advanced Breast Cancer

LOGIN or REGISTER to access this content

Introduction

Learning Objectives

Please feed back on these touchEXPERT OPINIONS on the following:(scale 1–5, 1 strongly disagree; 5 strongly agree).

touchCONGRESS Expert Interviews:
Advanced Breast Cancer

Please feed back on these touchEXPERT OPINIONS on the following:
(scale 1–5, 1 strongly disagree; 5 strongly agree).